{"product_id":"megf9-antibody-multiple-epidermal-growth-factor-like-domains-protein-9-bha17130002","title":"MEGF9 Antibody \/ Multiple epidermal growth factor-like domains protein 9","description":"\u003ch2\u003eOverview\u003c\/h2\u003e \u003cp\u003eMEGF9 Antibody \/ Multiple epidermal growth factor-like domains protein 9 is an antibody targeting \u003cstrong\u003eMEGF9\u003c\/strong\u003e, raised in \u003cstrong\u003eRabbit\u003c\/strong\u003e for protein detection and localization studies where these specifications are required.\u003c\/p\u003e \u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e \u003cul\u003e \u003cli\u003e\n\u003cstrong\u003eTarget:\u003c\/strong\u003e MEGF9.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eAntibody identity:\u003c\/strong\u003e Polyclonal (rabbit origin); Rabbit IgG.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eConjugate\/label:\u003c\/strong\u003e Unconjugated (affects detection chemistry and multiplex compatibility).\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Antigen affinity purified.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eSpecies reactivity:\u003c\/strong\u003e Human.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eListed applications:\u003c\/strong\u003e WB, ELISA (refer to on-page specifications for application-specific guidance).\u003c\/li\u003e \u003c\/ul\u003e  \u003ch2\u003eBiological background\u003c\/h2\u003e \u003cp\u003eMEGF9 (Multiple EGF-like domains protein 9; also EGF-like protein 5) is a 63 kDa (predicted) novel transmembrane glycoprotein that shares some homology to beta -chains of laminin. It is expressed by hepatocytes, cerebellar Purkinje cells, Schwann cells, keratinocytes and intestinal epithelium. MEGF9 is suggested to participate in cell motility, and its absence correlates with tumor cell migration. Mature human MEGF9 is 572 amino acids (aa) in length. It is a single span type I transmembrane protein that contains a 484 aa extracellular region (aa 31-514) plus a 68 aa C-terminal cytoplasmic domain. The extracellular region possesses a lengthy Pro-rich region (aa 55-200), followed by five EGF-like domains (aa 204-451).\u003c\/p\u003e \u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e \u003cul\u003e \u003cli\u003eComparative expression profiling across cell types, tissues, or perturbations (e.g., drug treatment, genetic editing, or differentiation).\u003c\/li\u003e \u003cli\u003eSubcellular localization and trafficking studies, including co-localization with pathway markers in microscopy-based assays.\u003c\/li\u003e \u003cli\u003eIntegration of protein-level measurements with transcriptomics or proteomics to relate abundance to regulation and phenotype.\u003c\/li\u003e \u003c\/ul\u003e \u003ch2\u003eCommon research applications\u003c\/h2\u003e \u003cul\u003e \u003cli\u003eWestern blotting: researchers commonly compare relative signal levels across conditions and use appropriate negative\/positive controls for interpretation.\u003c\/li\u003e \u003cli\u003eELISA: researchers commonly compare relative signal levels across conditions and use appropriate negative\/positive controls for interpretation.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eInterpretation should account for antibody-dependent factors such as epitope accessibility, isoforms, and sample preparation differences across workflows.\u003c\/p\u003e \u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e \u003cul\u003e \u003cli\u003e\n\u003cstrong\u003eIsoforms and PTMs:\u003c\/strong\u003e many targets have multiple isoforms and post-translational modifications that can shift apparent signal or localization; interpret bands\/signals accordingly.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eEpitope context:\u003c\/strong\u003e binding can depend on protein conformation and sample processing; region information in the title\/immunogen can help anticipate what may be detected.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eSpecies differences:\u003c\/strong\u003e predicted or validated reactivity may vary by ortholog sequence and sample context; confirm in your model system.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eControl concepts:\u003c\/strong\u003e include negative controls (no-primary\/isotype), and where possible genetic controls (KO\/KD) or independent antibodies to strengthen conclusions.\u003c\/li\u003e \u003c\/ul\u003e \u003c!-- Sources (internal): - UniProtKB entry Q9H1U4 — UniProt — https:\/\/www.uniprot.org\/uniprotkb\/Q9H1U4 - Gene search: MEGF9 — NCBI Gene — https:\/\/www.ncbi.nlm.nih.gov\/gene\/?term=MEGF9 - Ensembl search: MEGF9 — Ensembl — https:\/\/www.ensembl.org\/Multi\/Search\/Results?q=MEGF9 - PubMed search: MEGF9 antibody — PubMed — https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=MEGF9+antibody - Reactome search: MEGF9 — Reactome — https:\/\/reactome.org\/content\/query?q=MEGF9 --\u003e","brand":"NSJ Bioreagents","offers":[{"title":"0.5mg\/ml if reconstituted with 0.2ml sterile DI water \/ 100 ug","offer_id":53046479552877,"sku":"RQ8445","price":449.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/get_image_b5c135c4-9480-412f-bee6-8ceedc0235ed.jpg?v=1772000853","url":"https:\/\/www.ebiohippo.com\/products\/megf9-antibody-multiple-epidermal-growth-factor-like-domains-protein-9-bha17130002","provider":"BioHippo","version":"1.0","type":"link"}